SCHEMBL1380780

SCHEMBL1380780

Cc1ccc(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)onc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 19/20 0.58
▸ PDGFRB P09619 10/20 0.58
▸ KDR P35968 17/20 0.57
▸ KIT P10721 9/20 0.57
▸ CSF1R P07333 3/20 0.50
▸ FLT1 P17948 3/20 0.50
▸ AURKA O14965 2/20 0.50
▸ ROCK2 O75116 2/20 0.50
▸ RPS6KA5 O75582 2/20 0.50
▸ MAP4K4 O95819 2/20 0.50
▸ NTRK1 P04629 2/20 0.50
▸ LCK P06239 2/20 0.50
▸ FYN P06241 2/20 0.50
▸ LYN P07948 2/20 0.50
▸ RET P07949 2/20 0.50
▸ PIM1 P11309 2/20 0.50
▸ FGFR1 P11362 2/20 0.50
▸ FER P16591 2/20 0.50
▸ RPS6KB1 P23443 2/20 0.50
▸ MARK3 P27448 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4735877 0.92 FLT3 (0.58) FLT3PDGFRBKDRKITCSF1R
SCHEMBL4739605 0.90 KDR (0.67) FLT3PDGFRBKDRKITCSF1R
SCHEMBL1379853 0.89 KDR (0.61) FLT3PDGFRBKDRKITCSF1R
SCHEMBL4739508 0.88 KDR (0.63) FLT3PDGFRBKDRKITCSF1R
SCHEMBL4735746 0.88 KDR (0.68) FLT3PDGFRBKDRKITCSF1R
SCHEMBL1381417 0.88 KDR (0.66) FLT3PDGFRBKDRKITCSF1R
SCHEMBL4787011 0.87 KDR (0.66) FLT3PDGFRBKDRKITCSF1R
SCHEMBL1384184 0.87 KDR (0.59) FLT3PDGFRBKDRKITCSF1R
SCHEMBL5251843 0.87 KDR (0.58) FLT3PDGFRBKDRKITCSF1R
SCHEMBL1385557 0.87 KDR (0.66) FLT3PDGFRBKDRKITCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 — — 2011-11-09 — — JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 — — WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 — — EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 — — WO claimed
Send feedback